Recently, Wuhan Thalys Biotechnology Co.,Ltd. ("Thalys") announced that it has signed a contract with Norwegian high-tech molecular diagnostic company Genetic Analysis ("GA") for the laboratory self-built project testing (LDT) for the Chinese market. Develop and evaluate cooperation agreements. The two parties will jointly evaluate and develop innovative diagnostic solutions based on intestinal microecology to meet the needs of China's rapidly growing intestinal microecology market. Thalys will fully rely on the Group's independent medical laboratory in Shanghai to further develop and distribute the target-based multi-omics GA map® analysis technology for the identification and characterization of irritable bowel syndrome (IBS) and inflammatory diseases in the eastern population. Dysbacteriosis in patients with enteritis (IBD), helping to unlock and establish criteria for the assessment of gut microecology unique to eastern populations.

Adhering to the corporate mission of innovating for a healthy China, Thalys continues to explore the world's top technologies in the field of high-end IVD. The intestinal microecology project in cooperation with GA is a new and untouched field in the molecular diagnosis market, which means that Thalys leads the innovation of the entire intestinal microecology industry in China.

On January 12, VivaChek Biotech (Hangzhou) Co., Ltd. ("VivaChek") and Guangdong Lexin Medical Electronics Co., Ltd. ("Lexin Medical") reached a strategic partnership. Both parties will give full play to their respective fields. With the advantages of technology and resources, they will carry out all-round cooperation in research and development, sales and operation of blood glucose meter projects.